AN IN VITRO TEST PREDICTIVE OF THE IN VIVO B CELL RITUXIMAB-TRIGGERED DEPLETION, UNDERLINES THE POTENTIAL THERAPEUTIC INTEREST OF A RECOMBINANT ANTI-CD20 IGA IN B-CLL PATIENTS

被引：0
|
作者：
Congy, N. [1 ]
Ysebaert, L. [2 ]
Apoil, P. [1 ]
Tiraby, G. [3 ]
Drocourt, D. [3 ]
Abbal, M. [1 ]
Blancher, A. [1 ]
机构：
[1] Univ Paul Sabatier, EA 3O34, Toulouse, France
[2] CHU Purpan, INSERM, U563, Toulouse, France
[3] Cayla Invivogen, Toulouse, France
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2010年 / 95卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1263
引用
收藏
页码：515 / 515
页数：1
相关论文
共 50 条
  • [41] GA101 IS A HIGHLY EFFICACIOUS TYPE II ANTI-CD20 MONOCLONAL ANTIBODY THAT INDUCES DIRECT CELL DEATH BUT LOW COMPLEMENT MEDIATED CYTOTOXICITY IN B-CLL WHOLE BLOOD ASSAYS
    Bologna, L.
    Golay, J.
    Gotti, E.
    Rambaldi, A.
    Intermesoli, T.
    Introna, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 184 - 184
  • [42] Rituximab (anti-CD20 monoclonal antibody) immunotherapy in patients with B-cell non-Hodgkin's lymphoma:: highly effective treatment of residual disease
    Papajík, T
    Szotkowski, T
    Raida, L
    Hubáek, J
    Faber, E
    Hlusí, A
    Vondráková, J
    Pikalová, Z
    Jedliková, K
    Jarosová, M
    Indrák, K
    LEUKEMIA, 2001, 15 (03) : 510 - 510
  • [43] Preliminary experience with yttrium-90-labeled Rituximab (chimeric anti-CD20 antibody) in patients with relapsed and refractory B-cell NHL - a prospective trial
    Thakral, P.
    Lata, S.
    Singla, S.
    Sharma, A.
    Bal, C.
    Malhotra, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S294 - S294
  • [44] A novel platform for radioimmunotherapy.: Extracorporeal depletion of biotinylated and 90Y-labeled anti-CD20 in patients with refractory B-cell lymphoma.
    Linden, O
    Kurkus, J
    Garkavij, M
    Cavallin-Ståhl, E
    Ohlsson, T
    Nilsson, R
    Sandberg, BE
    Ljungberg, M
    Strand, SE
    Tennvall, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 576S - 576S
  • [45] Mutation P331S in the Fc Domain of an Anti-CD20 SMIP™ Protein Confers Impaired in vivo B Cell Depletion Activity in Lymphoid Tissues of Cynomolgus Monkeys
    Seth, Nilufer
    Nickerson-Nutter, Cheryl
    Medley, Quintus
    Tchistiakova, Lioudmila
    Olland, Stephane
    Zollner, Richard
    Brady, William
    Mohler, Kendall
    Baum, Peter
    Wahl, Alan
    Gill, Davinder
    Collins, Mary
    Brady, William
    CLINICAL IMMUNOLOGY, 2009, 131 : S88 - S88
  • [46] The mechanism through which type II (tositumomab-like) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion
    Beers, S. A.
    French, R. R.
    Chan, H. T.
    James, S.
    Bruger, A. M.
    Ahuja, A.
    Shlomchik, M. J.
    Glennie, M. J.
    Cragg, M. S.
    IMMUNOLOGY, 2008, 125 : 52 - 52
  • [47] Ublituximab (TGTX-1101), A Novel Anti-CD20 Monoclonal Antibody (mAb), Demonstrates Activity in Rituximab-Sensitive and Rituximab-resistant B Non-Hodgkin Lymphoma (B-NHL) Pre-Clinical In vitro and in Vivo models
    Miller, John
    Barth, Matthew J.
    Mavis, Cory
    Tsai, Ping-Chiao
    Klener, Pavel, Jr.
    Hernandez-Ilizaliturri, Francisco
    Czuczman, Myron S.
    BLOOD, 2012, 120 (21)
  • [48] Quality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkin’s lymphoma: results of a prospective randomized controlled trial
    Mathias Witzens-Harig
    Monika Reiz
    Christiane Heiß
    Axel Benner
    Manfred Hensel
    Kai Neben
    Peter Dreger
    Alwin Kraemer
    Anthony D. Ho
    Annals of Hematology, 2009, 88
  • [49] Quality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkin's lymphoma: results of a prospective randomized controlled trial
    Witzens-Harig, Mathias
    Reiz, Monika
    Heiss, Christiane
    Benner, Axel
    Hensel, Manfred
    Neben, Kai
    Dreger, Peter
    Kraemer, Alwin
    Ho, Anthony D.
    ANNALS OF HEMATOLOGY, 2009, 88 (01) : 51 - 57
  • [50] Serum BAFF and APRIL Levels, T-Lymphocyte Subsets, and Immunoglobulins after B-Cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Myalgic Encephalopathy/Chronic Fatigue Syndrome
    Lunde, Sigrid
    Kristoffersen, Einar K.
    Sapkota, Dipak
    Risa, Kristin
    Dahl, Olav
    Bruland, Ove
    Mella, Olav
    Fluge, Oystein
    PLOS ONE, 2016, 11 (08):
12345